Choudhury, Yukti
Toh, Yi Chin
Xing, Jiangwa
Qu, Yinghua
Poh, Jonathan
Li, Huan
Tan, Hui Shan
Kanesvaran, Ravindran
Yu, Hanry
Tan, Min-Han
Article History
Received: 22 February 2016
Accepted: 19 December 2016
First Online: 25 January 2017
Change Date: 25 April 2017
Change Type: Update
Change Details: A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has not been fixed in the paper. In addition, the version of this Article previously published omitted Hanry Yu as a corresponding author. Correspondence and request for materials should also be addressed to hyu@ibn.a-star.edu.sg. This has now been corrected in the HTML and PDF versions of the Article.
Change Date: 25 April 2017
Change Type: Erratum
Change Details: Scientific Reports 7: Article number: 41238; published online: 25 January 2017; updated: 25 April 2017 The original version of this Article contained an error in the spelling of the author Huan Li, which was incorrectly given as Li Huan. The Author Contributions Statement, Study concept and design: Y.
Competing interests
: Ravindran Kanesvaran has received research funding from Sanofi and is on advisory board of Pfizer, Astellas and Bayer. Hanry Yu has ownership in and is on advisory board of InvitroCue Pte Ltd and has received research funding from Janssen. Min-Han Tan has received research funding from Pfizer. Yukti Choudhury and Min-Han Tan have filed a patent filed for a patent involving molecular diagnostics in renal cell carcinoma. The remaining authors have declared no competing financial interests.